

Juvenai

The longevity platform for Latin America.

Santiago, Chile · August 2026 · juvenai.com

Backed by  PatagoniaVS



World-class founders & scientists



René Vidal, MBA

CO-FOUNDER & CEO

30+ years in software and AI. Founder and former CEO of Amisoft.ai, a Chilean AI company fully acquired by Vesta Software Group in 2024.



Dr. Francisco Altimiras, PhD.

CO-FOUNDER & CTO

15+ years in data science and biotechnology. Former CTO of Instacrops, a Y Combinator backed company. Expert in technology strategy.



Dr. Christian González, PhD.

CO-FOUNDER & CSO

Longevity expert, Former Director of GERO (Geroscience Center for Brain Health and Metabolism) and Adjunct Professor at the Buck Institute for Research on Aging.



Dr. Héctor Allende-Cid, PhD.

CO-FOUNDER & CHIEF OF AI

AI expert and Former Scientist at Fraunhofer IAIS in Germany. Part of the team behind Teuken, Germany's first multilingual LLM. Specialist in ML and applied AI.

Medicine waits for you to **get sick**

Aging is the single largest risk factor for the diseases that will actually kill you, and it is measurable and modifiable years before diagnosis.

Preventive care in Latin America is an annual panel nobody explains, filed and forgotten.



01

Hallmarks of aging

Biological mechanisms that drive age-related disease. None of them appear on a standard lab report.



02

Purchasing power

Chilean households cannot absorb US longevity-clinic pricing. The category has to be rebuilt for the region, not translated.




03

Regional players


No Latin American company owns longevity as a consumer health category today.

The same age can hide very different **biological trajectories.**



A longevity program, not a lab report

Biological age from 50+ blood biomarkers and continuous wearable data, converted into a personalized plan with clinical supervision and a quarterly retest. The loop is the product.



QUARTERLY RETEST ↻

01

Measure

Blood biomarkers plus a full epigenetic panel to estimate biological age and pace of aging.

02

Interpret

AI turns the panel into plain-language findings across 10 health categories, reviewed one-on-one by a clinician.

03

Act


A personalized plan of nutrition, movement, sleep and supplements, tracked daily with wearable data flowing in.

04

Prove

A new biomarker panel every quarter, included in the membership, so the member sees whether their biological age moved.

One platform, **three surfaces**



Web application

Biological age decoded, biomarkers, digital twin, clinical record, data analytics and lab orders.



Wearables integration

HRV, sleep and steps with 28-day baselines. Apple Health and Google Health Integrations.



Mobile application

Food logging by text, photo or barcode; habit tracking. Available in App Store and Google Play.

Built on peer-reviewed science



PhenoAge

Published biological-age algorithm implemented against the original Gompertz mortality model, with documented test cases.



Epigenetic clock

Full DNA-methylation panel to estimate biological age and pace of aging, offered directly in the app.



Multi-omics

Genomics, microbiome and gene expression: AlphaFold structures, protein networks, taxonomic and diversity analysis.



AI teleconsultation

Live note-taking during the call and an automatic SOAP note, always approved by the physician before it enters the record.



Digital twin

Anatomical avatar mapping every biomarker to the organ system it affects, so findings are legible to a non-expert.




Longitudinal record

Every panel, consultation, prescription and daily log in one timeline. This is the asset that compounds.

A funded category with no regional owner

2026 Forecast

TAM · Global longevity clinics



SAM · Latin America mHealth



Context · LatAm digital health



SOM · CHILE FIRST


Where we have the clinical study, the lab network and the regulatory footing. Brazil is 39.4% of regional mHealth, which is why it is second.

THE CATEGORY IS BEING FUNDED

Function Health raised USD 298M at a USD 2.5B valuation, then cut to USD 365/yr. Prices are compressing toward where we already sit.

Chile, Ecuador, Brazil, then the **United States**

One product, four sequenced markets. Each stage funds the credibility required for the next.



Membership, with diagnostics on top

Essence

USD 49

Per Year

App, digital twin, AI guidance,
habit tracking

Wearable-only entry

Longevity

USD 199

Per Year

Home blood draw, lab orders,
out-of-range alerts.

Blood markers

Elite

USD 399

Per Year

Epigenetic and microbiome
panels, monthly AI report, cohort
benchmark.

Full panel

Four levers expand **ARPU**



International tier

USD 199 – 499 / year, dollar-priced for the US and expatriate market, sold from the same platform. The category anchors 5-10x above entry price; we anchor at 4x.




B2B2C white label

Per-seat contracts with clinics, insurers and employers running longevity programs under their brand. Already validated as a demand shape in the region.



Juvenai Band

Own-brand wearable sold into the existing member base. Adds a hardware margin line and removes third-party data dependency.




Diagnostics marketplace

Panels, supplements and follow-up testing sold through the app at a take rate, with negotiated laboratory pricing.



Lowest entry price in the category



Shipped and **running in production**




Web app live

app.juvenai.com serving biological age, pillars, clinical record and daily logging, bilingual, on our own domain.



Mobile apps

iOS and Android Apps: food logging, habit tracking, same account as web.




Wearables syncing

Continuous HRV, resting heart rate, sleep stages and steps with 28-day baselines, verified live in production.




AI teleconsultation

Video consultation with live note-taking and automatic SOAP notes, validated end to end with real physicians.



Diagnostics catalogue

Bookable panels with a mapped network of Chilean laboratories and their insurance coverage.



Data integrity audit

Every seeded biomarker audited line by line against source documents; inferred values removed and labelled.

Raising **USD 1M** pre-seed

Already raised: USD 100K pre-seed as part of Patagonia Venture Studio.



Clinical validation

Complete the JUVE-1 longitudinal study enrollment of +1000 patients and follow-up.



Revenue infrastructure

Self-serve billing and subscription management, so members can buy without a sales conversation.



Mobile and hardware

Grow the mobile apps and advance the Juvenai Band from development to a manufacturable device.



Brazil entry

Partnerships with preventive-medicine clinics and diagnostic networks, plus the localization that entry requires.



Juvenai

Aging is measurable. That makes it actionable.

The company that owns longevity as a consumer health category in Latin America, with the clinical evidence to defend it.

Raising USD 1M to close the loop between product and paying members.

Juvenai Santiago - Chile juvenai.com

Backed by  PatagoniaVS